Provided by Tiger Trade Technology Pte. Ltd.

SBP GROUP

5.435
+0.1853.52%
Volume:25.94M
Turnover:139.53M
Market Cap:101.54B
PE:35.81
High:5.470
Open:5.430
Low:5.230
Close:5.250
52wk High:8.647
52wk Low:4.136
Shares:18.68B
HK Float Shares:18.68B
Volume Ratio:0.67
T/O Rate:0.14%
Dividend:0.12
Dividend Rate:2.21%
EPS(LYR):0.152
ROE:14.07%
ROA:7.51%
PB:2.67
PE(LYR):35.81
PS:2.58

Loading ...

Movement Alert|SBP GROUP Rises 3.83% in Regular Trading, Beimosubai Plus Anlotinib Lung Squamous Cell Carcinoma Indication Approved

Market Focus
·
Aug 10

SK Hynix Greenlights 54 Trillion Won Chip Expansion; Beijing Slashes Homebuying Tax Threshold for Non-Local Families to One Year

Stock News
·
Aug 10

Sino Biopharmaceutical Says NMPA Approves Benmelstobart

Reuters
·
Aug 08

Sino Biopharma Unit Gets China Nod to Market Lung Cancer Drug

MT Newswires Live
·
Aug 07

SBP Group Receives Approval for New Lung Cancer Treatment Combination

Stock News
·
Aug 07

Sino Biopharma Wins China NMPA Approval for First-Line Squamous NSCLC Combo Therapy

Reuters
·
Aug 07

Sino Biopharmaceutical - Nmpa Approves Benmelstobart with Chemotherapy Followed by Anlotinib for First-Line Sq-Nsclc

THOMSON REUTERS
·
Aug 07

Sino Biopharmaceutical Stock Climbs 3.3% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 07

Movement Alert|SBP GROUP Rises 3.25% in Regular Trading, Multiple New Drug Approvals and Pipeline Milestones Drive Momentum

Market Focus
·
Aug 07

Sino Biopharm Unit Gets Marketing Nod for Anti-Inflammatory Analgesic in China

MT Newswires Live
·
Aug 06

Sino Biopharm (SBP Group) Secures NMPA Green Light and Four-Year Data Protection for Second-Generation Flurbiprofen Patch

Bulletin Express
·
Aug 06

Sino Biopharmaceutical - Second-Generation Flurbiprofen Patch Approved for Marketing

THOMSON REUTERS
·
Aug 06

Sino Biopharmaceutical to Review 1H26 Results and Potential Interim Dividend on 19 August 2026

Bulletin Express
·
Aug 06

Sino Biopharma Schedules Board Meeting to Review Interim Results, Consider Dividend

Reuters
·
Aug 06

Sino Biopharmaceutical Stock Slips 1.2% in Hong Kong

Dow Jones
·
Aug 05

Sino Biopharma Unit's Application for Lymphocytic Leukemia Drug Accepted in China

MT Newswires Live
·
Aug 04

Sino Biopharma Says China CDE Accepts NDA for Tqb3909 BCL-2 Inhibitor in Cll/sll

Reuters
·
Aug 04

Sino Biopharmaceutical - New Drug Application for Tqb3909 Tablet Accepted by China's Cde

THOMSON REUTERS
·
Aug 04

Sino Biopharma Unit Gets Breakthrough Therapy Designation for Cancer Drug in China

MT Newswires Live
·
Aug 03

SBP Group's Third Breakthrough Therapy Designation for TQB2102 Strengthens Its Position in HER2-Targeted Cancer Treatments

Stock News
·
Aug 03